DE602004005033D1 - Benzamidinhibitoren des p2x7-rezeptors - Google Patents

Benzamidinhibitoren des p2x7-rezeptors

Info

Publication number
DE602004005033D1
DE602004005033D1 DE602004005033T DE602004005033T DE602004005033D1 DE 602004005033 D1 DE602004005033 D1 DE 602004005033D1 DE 602004005033 T DE602004005033 T DE 602004005033T DE 602004005033 T DE602004005033 T DE 602004005033T DE 602004005033 D1 DE602004005033 D1 DE 602004005033D1
Authority
DE
Germany
Prior art keywords
receptor
benzamidinhibitors
disorders
copd
reperfusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004005033T
Other languages
English (en)
Other versions
DE602004005033T2 (de
Inventor
Mark Anthony Dombroski
Allen Jacob Duplantier
Chakrapani Subramanyam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of DE602004005033D1 publication Critical patent/DE602004005033D1/de
Application granted granted Critical
Publication of DE602004005033T2 publication Critical patent/DE602004005033T2/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
DE602004005033T 2003-05-12 2004-05-10 Benzamidinhibitoren des p2x7-rezeptors Active DE602004005033T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47000103P 2003-05-12 2003-05-12
US470001P 2003-05-12
PCT/IB2004/001525 WO2004099146A1 (en) 2003-05-12 2004-05-10 Benzamide inhibitors of the p2x7 receptor

Publications (2)

Publication Number Publication Date
DE602004005033D1 true DE602004005033D1 (de) 2007-04-12
DE602004005033T2 DE602004005033T2 (de) 2007-08-09

Family

ID=33435257

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004005033T Active DE602004005033T2 (de) 2003-05-12 2004-05-10 Benzamidinhibitoren des p2x7-rezeptors

Country Status (10)

Country Link
US (2) US7186742B2 (de)
EP (1) EP1626962B1 (de)
JP (1) JP4731468B2 (de)
AT (1) ATE355273T1 (de)
BR (1) BRPI0410349A (de)
CA (1) CA2525437C (de)
DE (1) DE602004005033T2 (de)
ES (2) ES2281801T3 (de)
MX (1) MXPA05012086A (de)
WO (1) WO2004099146A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8557501A1 (es) * 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
PA8591801A1 (es) * 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
US7071223B1 (en) 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
BRPI0410349A (pt) 2003-05-12 2006-05-30 Pfizer Prod Inc inibidores de benzamida do receptor p2x7
BRPI0512781A (pt) * 2004-06-29 2008-04-08 Pfizer Prod Inc método para preparação de derivados de 5-{4-(2-hidroxi-propil)-3,5-dioxo-4,5-diidro-3h-[1,2,4]tria zin-2-il}-benzamida através da desproteção dos precursores de protetores de hidroxila
CA2572119A1 (en) * 2004-06-29 2006-01-12 Warner-Lambert Company Llc Combination therapies utilizing benzamide inhibitors of the p2x7 receptor
KR20070083679A (ko) * 2004-09-29 2007-08-24 케마지스 리미티드 약학적으로 순수한 비정질 도네페닐 염산염의 제조를 위한정제된 도네페질 말레산염의 용도
US20080146612A1 (en) * 2005-01-27 2008-06-19 Astrazeneca Ab Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor
CN101304975A (zh) * 2005-11-09 2008-11-12 艾博特公司 P2x7受体拮抗剂及其用途
EP2091927B1 (de) 2006-11-09 2011-07-20 F. Hoffmann-La Roche AG Thiazol- und oxazolsubstituierte arylamide
US8501933B2 (en) 2006-11-09 2013-08-06 Roche Palo Alto Llc Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists
DK2124562T3 (en) * 2007-03-09 2016-08-01 Second Genome Inc BICYCLOHETEROARYLFORBINDELSER AS P2X7 modulators and uses thereof
MX2009010059A (es) * 2007-03-22 2009-10-12 Astrazeneca Ab Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
EA017250B1 (ru) * 2007-07-19 2012-11-30 Х. Лундбекк А/С 5-членные гетероциклические амиды и их применение для модуляции рецептора p2x
EP2203429A1 (de) * 2007-10-31 2010-07-07 Nissan Chemical Industries, Ltd. Pyridazinonderivate und ihre verwendung als p2x7-rezeptorhemmer
KR101405746B1 (ko) 2007-12-17 2014-06-10 에프. 호프만-라 로슈 아게 트리아졸 치환된 아릴아미드 유도체 및 ｐ２ｘ３ 및/또는 ｐ２ｘ２／３ 퓨린성 수용체 길항제로서의 용도
DK2234976T3 (da) * 2007-12-17 2013-06-24 Hoffmann La Roche Nye pyrazol-substituerede arylamider
CN101903355B (zh) 2007-12-17 2014-05-14 霍夫曼-拉罗奇有限公司 咪唑取代的芳基酰胺
BRPI0820838B8 (pt) 2007-12-17 2021-05-25 Hoffmann La Roche derivados de arilamida substituídos por tetrazol, composição farmacêutica que os compreende e seu uso como antagonistas do receptor purinérgico p2x3 e/ou p2x2/3
DK2105164T3 (da) 2008-03-25 2011-03-21 Affectis Pharmaceuticals Ag Nye P2X7R-antagonister og deres anvendelse
BRPI0922645A2 (pt) * 2008-12-16 2019-09-24 Hoffmann La Roche "arilamidas tiadiazol substituídas".
SG175232A1 (en) 2009-04-14 2011-12-29 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
CN102574778B (zh) 2009-06-22 2015-01-07 弗·哈夫曼-拉罗切有限公司 新的联苯基和苯基-吡啶酰胺类化合物
CN102803245B (zh) 2009-06-22 2015-02-11 弗·哈夫曼-拉罗切有限公司 作为p2x3和/或p2x2/3拮抗剂的吲哚、吲唑和苯并咪唑芳基酰胺类
CN102438989B (zh) 2009-06-22 2015-05-27 霍夫曼-拉罗奇有限公司 噁唑酮和吡咯烷酮取代的芳基酰胺
EA201290876A1 (ru) 2010-03-05 2013-03-29 Президент Энд Феллоуз Оф Гарвард Колледж Композиции индуцированных дендритных клеток и их использование
AU2011252351A1 (en) 2010-05-14 2012-10-11 Affectis Pharmaceuticals Ag Novel methods for the preparation of P2X7R antagonists
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
JP2014513671A (ja) * 2011-02-22 2014-06-05 アクテリオン ファーマシューティカルズ リミテッド Ｐ２ｘ７受容体アンタゴニストとしてのベンズアミド誘導体
WO2012129562A2 (en) * 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2013014587A1 (en) 2011-07-22 2013-01-31 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
CN102993096A (zh) * 2011-09-13 2013-03-27 宁波大学 一种n-吡唑酰胺衍生物及其制备方法
TWI576347B (zh) 2012-01-20 2017-04-01 艾克泰聯製藥有限公司 作為ｐ２ｘ受體拮抗劑之雜環醯胺衍生物
JP6254169B2 (ja) 2012-09-28 2017-12-27 ファイザー・インク ベンズアミドおよびヘテロベンズアミド化合物
TW201427947A (zh) 2012-10-12 2014-07-16 Lundbeck & Co As H 環狀胺
TWI598325B (zh) * 2012-10-12 2017-09-11 Ｈ 朗德貝克公司 苯甲醯胺類
SG11201504369SA (en) 2012-12-12 2015-07-30 Actelion Pharmaceuticals Ltd Indole carboxamide derivatives as p2x7 receptor antagonists
KR102232744B1 (ko) 2012-12-18 2021-03-26 이도르시아 파마슈티컬스 리미티드 Ｐ２ｘ７ 수용체 길항제로서의 인돌 카르복사미드 유도체
KR102220847B1 (ko) 2013-01-22 2021-02-26 이도르시아 파마슈티컬스 리미티드 Ｐ2ｘ7 수용체 길항제로서의 헤테로시클릭 아미드 유도체
EP2956135B1 (de) 2013-01-22 2016-11-16 Actelion Pharmaceuticals Ltd. Heterocyclische amidderivate als p2x7-rezeptorantagonisten
ES2900815T3 (es) 2013-03-15 2022-03-18 Scripps Research Inst Compuestos y métodos para inducir la condrogénesis
JP6422164B2 (ja) 2013-12-26 2018-11-14 塩野義製薬株式会社 含窒素６員環誘導体およびそれらを含有する医薬組成物
EP2905282A1 (de) 2014-02-05 2015-08-12 AXXAM S.p.A. Substituierte Thiazole oder Oxazole als P2X7-Rezeptorantagonisten
TWI715569B (zh) 2015-04-24 2021-01-11 日商塩野義製藥股份有限公司 ６員雜環衍生物及含有彼等之醫藥組合物
US10750742B2 (en) 2015-12-22 2020-08-25 Syngenta Participations Ag Pesticidally active pyrazole derivatives
EP3290416A1 (de) 2016-08-31 2018-03-07 AXXAM S.p.A. Substituierte n-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamid- und n-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamid- derivate und ihre verwendung als p2x7 rezeptor antagonist
EP3290417A1 (de) 2016-08-31 2018-03-07 AXXAM S.p.A. 2-chloro-n-[2-(1,3-thiazol-5-yl)ethyl]-5-(5-fluoropyrimidin-2-yl)-benzamide und ihre verwendung als p2x7 rezeptor antagonisten
CA3039458A1 (en) 2016-10-17 2018-04-26 Shionogi & Co., Ltd. Bicyclic nitrogen-containing heterocyclic derivatives and pharmaceutical composition comprising the same
EP3398941A1 (de) 2017-05-03 2018-11-07 AXXAM S.p.A. Heterozyklische p2x7-antagonisten
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2021151062A1 (en) * 2020-01-24 2021-07-29 The Trustees Of Princeton Univeristy Heterocyclic compounds and uses thereof
EP4015039A1 (de) 2020-12-18 2022-06-22 AXXAM S.p.A. Heterocyclische derivate als p2x7-rezeptor-antagonisten
WO2023031319A1 (en) 2021-09-03 2023-03-09 Axxam S.P.A. 2,4-dihydro-3h-1,2,4-triazol-3-one p2x7 antagonists

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR80558B (en) 1983-10-08 1985-02-06 Nippon Kayaku Kk Derivative of pyrazole and use thereof as a herbicide
US5128351A (en) * 1990-05-04 1992-07-07 American Cyanamid Company Bis-aryl amide and urea antagonists of platelet activating factor
US5077409A (en) * 1990-05-04 1991-12-31 American Cyanamid Company Method of preparing bis-aryl amide and urea antagonists of platelet activating factor
US5281571A (en) * 1990-10-18 1994-01-25 Monsanto Company Herbicidal benzoxazinone- and benzothiazinone-substituted pyrazoles
JPH06503564A (ja) 1990-12-17 1994-04-21 シエル・インターナシヨネイル・リサーチ・マーチヤツピイ・ベー・ウイ 殺菌性イソキノリン誘導体
GB9119467D0 (en) 1991-09-12 1991-10-23 Smithkline Beecham Corp Chemical compounds
US5686061A (en) * 1994-04-11 1997-11-11 The Board Of Regents Of The University Of Texas System Particulate contrast media derived from non-ionic water soluble contrast agents for CT enhancement of hepatic tumors
HRP950330A2 (en) * 1994-07-05 1997-10-31 Ciba Geigy Ag New herbicides
JP3144624B2 (ja) * 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
US6147101A (en) * 1995-06-02 2000-11-14 Kyorin Pharmaceutical Co., Ltd. N-benzyldioxothiazolidylbenzamide derivatives and process for producing the same
US6001862A (en) * 1995-06-02 1999-12-14 Kyorin Pharameuticals Co., Ltd. N-benzyldioxothiazolidylbenzamide derivatives and processes for preparing the same
US5672715A (en) * 1995-06-07 1997-09-30 Monsanto Company Herbicidal substituted 3-aryl-pyrazoles
JP3906935B2 (ja) * 1995-12-18 2007-04-18 杏林製薬株式会社 Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
US5939418A (en) * 1995-12-21 1999-08-17 The Dupont Merck Pharmaceutical Company Isoxazoline, isothiazoline and pyrazoline factor Xa inhibitors
WO1997036862A1 (en) * 1996-03-29 1997-10-09 G.D. Searle & Co. META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
DE19701287A1 (de) * 1997-01-16 1998-07-23 Wernicke & Co Gmbh Verfahren zum Erhöhen der Gebrauchsdauer von Schleifscheiben
EP1019375A1 (de) * 1997-03-25 2000-07-19 Astra Pharmaceuticals Limited Neue pyridinderivate und pharmazeutische zusammensetzungen die diese enthalten
WO1998043973A1 (de) 1997-03-27 1998-10-08 Novartis Ag Zwischenprodukte und verfahren zur herstellung von pyrimidinderivaten
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
US6297239B1 (en) * 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
SE9704546D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
JPH11318492A (ja) * 1998-03-09 1999-11-24 Aisin Seiki Co Ltd 蛍光発生性基質を含有する組成物
TR200003037T2 (tr) * 1998-04-20 2001-01-22 Fujisawa Pharmaceutical Co.,Ltd. CGMP-Fosfodiesteraz önleyicileri olarak antiranilik asit türevleri.
US6320078B1 (en) * 1998-07-24 2001-11-20 Mitsui Chemicals, Inc. Method of producing benzamide derivatives
FR2783519B1 (fr) * 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
DE19851184A1 (de) * 1998-11-06 2000-05-11 Aventis Pharma Gmbh N-Arylsulfonyl-aminosäure-omega-amide
DE69927050T2 (de) 1998-12-16 2006-06-29 Bayer Healthcare Ag Biphenylverbindungen und biphenyl-analoge als intergrin-antagonisten
SK13422001A3 (sk) * 1999-04-09 2002-05-09 Astrazeneca Ab Adamantánové deriváty
WO2000071512A1 (en) 1999-05-24 2000-11-30 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
SE9904505D0 (sv) * 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
TWI258462B (en) * 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE9904738D0 (sv) * 1999-12-22 1999-12-22 Astra Pharma Prod Novel compounds
DE10005284A1 (de) * 2000-02-07 2001-08-09 Bayer Ag Verfahren zur Herstellung von 1-Amino-3-aryl-uracilen
GB0006721D0 (en) * 2000-03-20 2000-05-10 Mitchell Thomas A Assessment methods and systems
AU2002221080A1 (en) * 2000-12-08 2002-06-18 Masami Kusaka Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparingthe same and use thereof
JP4160295B2 (ja) * 2000-12-08 2008-10-01 武田薬品工業株式会社 ３−ピリジル基を有する置換チアゾール誘導体、その製造法および用途
ES2249589T3 (es) * 2001-05-18 2006-04-01 Abbott Laboratories Trisustituido-n-((1s)-1,2,3,4-tetrahidro-1-naftalenil)benzamidas que inhiben receptores que contienen antagonistas p2x3 y p2x2/3.
WO2003042190A1 (en) * 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
PA8557501A1 (es) * 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
US7704995B2 (en) * 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
WO2003093297A2 (en) * 2002-05-03 2003-11-13 Exelixis, Inc. Protein kinase modulators and methods of use
EP1562911B1 (de) * 2002-11-01 2010-01-06 Vertex Pharmaceuticals Incorporated Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
US7071223B1 (en) 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
WO2004058731A1 (en) * 2002-12-31 2004-07-15 Pfizer Products Inc. Benzamide inhibitors of the p2x7 receptor
PA8591801A1 (es) * 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
BRPI0410349A (pt) 2003-05-12 2006-05-30 Pfizer Prod Inc inibidores de benzamida do receptor p2x7
TWM244656U (en) * 2003-08-27 2004-09-21 Hon Hai Prec Ind Co Ltd Hinge mechanism
BRPI0512781A (pt) * 2004-06-29 2008-04-08 Pfizer Prod Inc método para preparação de derivados de 5-{4-(2-hidroxi-propil)-3,5-dioxo-4,5-diidro-3h-[1,2,4]tria zin-2-il}-benzamida através da desproteção dos precursores de protetores de hidroxila
WO2006003513A1 (en) * 2004-06-29 2006-01-12 Pfizer Products Inc. Method for preparing 5-`4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3h-`1,2,4!-triazin-2-yl!benzamide derivatives with p2x7 inhibiting activity by reaction of the derivative unsubstituted in 4-position of the triazine with an oxiran in the presence of a lewis acid
CA2572119A1 (en) 2004-06-29 2006-01-12 Warner-Lambert Company Llc Combination therapies utilizing benzamide inhibitors of the p2x7 receptor

Also Published As

Publication number Publication date
JP4731468B2 (ja) 2011-07-27
CA2525437C (en) 2009-04-28
US7553972B2 (en) 2009-06-30
US20050009900A1 (en) 2005-01-13
JP2006525991A (ja) 2006-11-16
EP1626962B1 (de) 2007-02-28
WO2004099146A1 (en) 2004-11-18
BRPI0410349A (pt) 2006-05-30
ES2396565T3 (es) 2013-02-22
MXPA05012086A (es) 2006-02-22
EP1626962A1 (de) 2006-02-22
ES2281801T3 (es) 2007-10-01
DE602004005033T2 (de) 2007-08-09
CA2525437A1 (en) 2004-11-18
ATE355273T1 (de) 2006-03-15
US20070142329A1 (en) 2007-06-21
US7186742B2 (en) 2007-03-06

Similar Documents

Publication Publication Date Title
DE602004005033D1 (de) Benzamidinhibitoren des p2x7-rezeptors
MY141984A (en) Benzamide inhibitors of the p2x7 receptor
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
MXJL05000010A (es) Compuestos de fenil-aza-benzimidazol para modular la ige e inhibir la proliferacion celular.
DE602004013563D1 (de) Rantagonisten
ATE533766T1 (de) Chinolinderivate als ep4-antagonisten
NO20056161L (no) Formuleringer for behandling av artrittilstander
EA200801362A1 (ru) Пиримидинил бензотиофеновые соединения
MA33926B1 (fr) Aminopyrimidines en tant qu'inhibiteurs de la syk
BR0317844A (pt) Inibidores de benzamida do receptor p2x7
NO20030896D0 (no) Nye dipeptidyl-peptidase IV-inhibitorer og deres anvendelse som anti-kreftmidler
EA200801372A1 (ru) Способы получения замещенных пиримидинов
NO20075268L (no) Fremgangsmate for fremstilling av opioidmodulatorer
NO20073790L (no) Kjemiske forbindelser
NO20073788L (no) Kjemiske forbindelser
NO20060230L (no) Nye aminobenzofenonforbindelser
NO20055741D0 (no) Nye kjemiske forbindelser
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
NO20076413L (no) Multisykliske forbindelser og fremgangsmater for deres anvendelse
TW200628463A (en) Heteroaryl compounds
TW200603798A (en) Disalt inhibitors of il-12 production
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
EA200870465A1 (ru) Антагонисты рецептора il-8
EA201070423A1 (ru) Диарильные соединения оксадиазолов
MXJL03000027A (es) Compuestos de benzimidazol para modular la ige e inhibir la proliferacion celular.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition